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A B S T R A C T
Purpose: Juvenile myoclonic epilepsy (JME) is a widely accepted epilepsy syndrome. Factors that are
potentially predictive for seizure outcome in JME are not entirely clear yet. In the current study, we tried
to identify factors that are potentially predictive for seizure outcome in patients with JME.
Method: In this case–control study all patients with a clinical diagnosis of JME were recruited at the
outpatient epilepsy clinic at Shiraz University of Medical Sciences from 2008 to 2012. All patients
were followed for at least 18 months. We divided the patients into two groups: patients who were
seizure free in the last 12 months of their follow-up period and those who had any seizures (i.e.,
generalized tonic-clonic (GTC), myoclonic or absences).
Results: 116 patients were studied. Sixty-eight patients were seizure free in the last 12 months of their
follow-up and 48 patients had at least one seizure of any type. Shorter follow-up period, drugs other than
valproate in the drug regimen, and poor drug adherence were signiﬁcantly more frequent among those
who were not seizure free.
Conclusion: A correct diagnosis of JME does not guarantee an optimal response to therapy. Poorer drug
adherence might result in more seizures; this should be highlighted for patients in every single visit.
Longer follow-up gives the treating physician more time to adjust the drug(s) and formulate a plan that is
appropriate for patients with difﬁcult to treat seizures. We recommend valproate if seizure control is the
main objective.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Juvenile myoclonic epilepsy (JME) is a widely accepted
syndrome of idiopathic generalized epilepsies (IGEs) with myo-
clonic seizures with or without other seizure types (e.g.,
generalized tonic-clonic seizures or absences), with age of onset
often in adolescence or young adulthood and with particular EEG
features including generalized spikes-waves/polyspikes and a
normal background.1,2 Juvenile myoclonic epilepsy is one of the
most common epilepsy syndromes. Frequency of JME is about 9%
of all epilepsies.2 Juvenile myoclonic epilepsy is often character-
ized by excellent response to treatment, if diagnosed correctly.3* Corresponding author at: Neurosciences Research Center, Shiraz University of
Medical Sciences, Shiraz, Iran. Tel.: +98 9352274990; fax: +98 7116121065.
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1059-1311/ 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reHowever, drug selection and treatment plan should be individual-
ized, considering various factors including drug efﬁcacy, patient’s
gender, age, and comorbidities, among other factors. Besides, the
long-term seizure outcome of JME is still controversial and factors
that are potentially predictive for seizure outcome are not entirely
clear yet.4
In the current study, we tried to identify factors that are
potentially predictive for seizure outcome in patients with juvenile
myoclonic epilepsy. Identiﬁcation of these predictors can poten-
tially increase the ability of physicians to manage their patients
more appropriately.
2. Methods and material
In this case–control study all patients with a clinical diagnosis
of JME were recruited at the outpatient epilepsy clinic at Shiraz
University of Medical Sciences from September 2008 to November
2012. The diagnosis of JME was made exclusively by the onlyserved.
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based on clinical grounds and electroencephalographic ﬁndings,
and all patients had to be under the care of the epileptologist at our
institution for at least 18 months. We considered the ﬁrst six
months of their follow-up as the time period to formulate an
individualized treatment plan and adjust the drug regimen
according to the patient’s proﬁle and response. Once JME has
been diagnosed, an anti-epileptic drug (AED) appropriate for that
condition may be prescribed. Our main goal of treatment was to
prevent future seizures from recurring. Treatment was typically
started with one of the ﬁrst line AEDs. First line drugs should be
effective and well tolerated. For generalized epilepsies, ﬁrst line
drugs include valproate, lamotrigine, levetiracetam, and topir-
amate among others.5 Our general strategy was to prescribe
valproate for men and lamotrigine for women, considering other
patient’s proﬁles (e.g., comorbidity, drug history, etc.). Levetir-
acetam is very expensive in Iran and is not covered by many
insurance policies. If a ﬁrst line drug controlled seizures and did
not cause side effects, therapeutic adjustments were not needed. If
seizures persisted, the medication regimen was adjusted and
another AED (e.g., levetiracetam, topiramate, etc.) was replaced the
ﬁrst AED slowly. If two monotherapies failed, we formulated a
polytherapy regimen for the patient, considering the trouble
making seizure type(s) and the patient’s proﬁle.
We divided the patients into two groups: patients who were
seizure free in the last 12 months of their follow-up period and
those who had any seizures (i.e., generalized tonic-clonic,
myoclonic or absences) in that time period. Age, gender, age at
seizure onset, seizure type(s) and their frequencies, epilepsy risk
factors (including history of febrile seizure, positive family history
of epilepsy, and parental consanguinity), social history (including
tobacco and alcohol consumption) and EEG ﬁndings of all patients
were registered routinely. Demographic variables and relevant
clinical and EEG variables were summarized descriptively to
characterize the study population. Statistical analyses were
performed using Chi square, Fisher’s Exact and Mann–Whitney
tests to determine potentially signiﬁcant differences, and a P value
less than 0.05 was considered signiﬁcant. This study was
conducted with the approval by Shiraz University of Medical
Sciences Review Board.Table 1
Comparison of demographic and clinical characteristics of patients with JME, with or w
Variables Sei
(68
Sex ratio (female to male) 46/
Age of seizure onset 15.
Disease duration prior to the ﬁrst visit 8 
Duration of follow-up 37.
Age at the ﬁrst visit 23.
Already on AED at the ﬁrst visit 51 
Tobacco consumption 2 (
Alcohol consumption 0 
History of monthly GTCSs before the ﬁrst visit 10 
History of absence seizures before the ﬁrst visit 27 
History of daily myoclonic seizures before the ﬁrst visit 14 
Parental consanguinitya 24 
Family history of epilepsy (ﬁrst, second, or third degree relatives) 23 
History of febrile seizure 3 (
History of status epilepticus before the ﬁrst visit 5 (
Monotherapy regimen 52 
Valproate in the drug regimen (as mono- or polytherapy) 48 
Good drug adherence 58 
Medical comorbidity 20 
Abnormal MRI ﬁndings 4/2
Signiﬁcant differences are in bold.
a Consanguinity (cousin to cousin marriage) is a common practice in the Middle Eas3. Results
During the study period, 116 patients with JME were eligible to
enter into the study. Sixty-eight patients were seizure free in the last
12 months of their follow-up and 48 patients had at least one seizure
of any type. Demographic and clinical characteristics of these two
groups of patients are shown and compared in Table 1. As it is
shown, in the univariate analysis, patients who were seizure free in
their follow-up had longer duration of follow-up, valproate in their
drug regimen and a better drug adherence, while those who
experienced seizures had more frequent generalized tonic-clonic
seizures (GTCS) before their ﬁrst visit and more often reported
alcohol and tobacco consumption. In the second step, we performed
binary logistic regression on the variables with signiﬁcant P-values
in univariate analysis (mentioned above). The full model was
statistically signiﬁcant X2 (6, N = 116) = 29.37, P < 0.001, indicating
that the model was able to distinguish between seizure free patients
and those who experienced seizures and correctly classify them in
71.6% of cases. Among all six independent variables (duration of
follow-up, tobacco consumption, alcohol consumption, history of
monthly GTCSs before the ﬁrst visit, valproate in the drug regimen
and good drug adherence), only three variables made a unique
statistically signiﬁcant contribution to the model, as follows: good
drug adherence (P = 0.02, OR = 3.09, 95% CI: 1.1–8.2); valproate in
the drug regimen (P = 0.02, OR = 2.8, 95% CI: 1.1–7.6); and duration
of follow-up (P = 0.01, OR = 1.06, 95% CI: 1.01–1.1). The median dose
of valproate was 800–1000 mg per day in both groups in the follow-
up visits (at 15 months, 27 months and 39 months of follow-up
visits). Electroencephalographic ﬁndings of these two groups of
patients are shown and compared in Table 2.
4. Discussion
Juvenile myoclonic epilepsy (JME) is a common epilepsy
syndrome.2 Juvenile myoclonic epilepsy is often characterized
by excellent response to treatment,3 but delay to a correct
diagnosis and consequently, choosing an inappropriate or subop-
timal agent may result in uncontrolled seizures in many patients.6
Besides, even a correct diagnosis does not guarantee an optimal
response to therapy and many patients suffer from ongoingithout seizures in their follow-up.
zure free patients
 patients)
Patients with seizure(s)
(48 patients)
P value
22 32/16 0.9
4  4.6 years 16  3.2 years 0.4
 7.1 years 10  12.2 years 0.6
2  8.4 months 33.2  10.3 months 0.02
1  7.5 years 24.9  8.8 years 0.2
(75%) 38 (79.2%) 0.6
2.9%) 7 (14.5%) 0.02
5 (10.4%) 0.01
(14.7%) 15 (31.2%) 0.03
(39.7%) 18 (37.5%) 0.8
(20.5%) 12 (25%) 0.5
(35.2%) 18 (37.5%) 0.8
(33.8%) 22 (45.8%) 0.2
4.4%) 1 (2%) 0.6
7.3%) 0 0.07
(76.4%) 31 (64.5%) 0.16
(70.5%) 23 (47.9%) 0.01
(85.2%) 30 (62.5%) 0.005
(29.4%) 21 (44.6%) 0.1
7 (17.3%) 5/16 (31.2%) 0.3
t.
Table 2
Comparison of the EEG ﬁndings in patients with JME, with or without seizures in
their follow-up.
Variables Seizure free
patients
(68 patients)
Patients with
seizure(s)
(48 patients)
P value
Generalized spike-waves 15 (22.1%) 17 (35.5%) 0.1
Generalized spike-waves
and Polyspikes
28 (41.2%) 12 (25%) 0.07
Polyspike-waves only 9 (13.2%) 6 (12.5%) 0.9
Normal 16 (23.5%) 13 (27%) 0.6
Photoparoxysmal response 4 (5.8%) 2 (4.2%), 1
Focal abnormalities 2 (2.9%) 1 (2.1%) 1
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study, 58.6% of our patients with JME responded well to their
treatment plan, while 41.4% experienced seizures (GTCSs, absences
or myoclonic jerks) in their follow up. This ﬁgure is higher than
some previous reports.7 This discrepancy might be due to the
referral nature of our clinic or alternatively, the method of the
study. We considered all seizure types including rare myoclonic
jerks and absences in the follow up period; while others probably
considered only GTCSs (74% of our patients were free of GTCSs in
their follow up visits).
When we compared patients who were seizure free with those
who experienced any seizure(s) in their follow up in a binary
logistic regression analysis, we observed that shorter follow up
period; AEDs other than valproate in the drug regimen; and poor
drug adherence were signiﬁcantly more frequent among those
who were not seizure free. Electroencephalography is a valuable
ancillary test in making the diagnosis of JME.8 In previous studies
conﬂicting results were observed about the role of EEG and its
association with treatment response in patients with JME. In one
retrospective study, focal EEG abnormalities increased the chances
(though, it did not correlate with) of lack of response to valproate
in these patients.9 In another retrospective study, EEG asymme-
tries were not associated with resistance to treatment in patients
with JME.10 In our study, EEG could not predict seizure outcome in
patients with JME. Longer follow up gives the treating physician
more time to adjust the drug(s) and formulate a plan that is
appropriate for patients with difﬁcult to treat seizures. Poor drug
adherence is an important factor in causing seizures in patients
with epilepsy, particularly those with JME. In a study done nine
years ago in the same region, drug adherence was satisfactory in
72% of the patients,11 which is very similar with the current
situation (75% in the current study). Drug adherence had a very
signiﬁcant contribution in the model that distinguished between
seizure-free patients and those who experienced seizures, in the
current study. This means poorer drug adherence might result in
more seizures in patients with JME; something that should be
highlighted for patients in every single visit. It is important to tell
the patients that JME is often characterized by excellent response
to treatment only if treatment is taken regularly! Superiority of
valproate versus lamotrigine treatment in idiopathic generalized
epilepsy syndromes including JME has been observed in many
previous studies.12,13 We indirectly had the same observation in
our study, as those taking valproate showed better outcome with
regard to seizure control compared with those taking other AEDs.
In patients with JME and particularly those with difﬁcult to treat
seizures, we recommend valproate, if seizure control is the mainobjective. However, when pregnancy is contemplated, the patient
and her family should be informed that valproate is associated
with the highest risk for major congenital malformations, and it
might also affect cognitive and behavioral development of
offspring. This creates a signiﬁcant headache when trying to
choose the ‘‘right’’ drug for most young women with JME.14
5. Limitations of the study
(1) This was a clinic-based series and may not represent the full
spectrum of JME.
(2) The population was heterogeneous as some were untreated
(27 patients) and others have been pre-treated (89 patients).
Study of the untreated patients (seizure free (17 patients) and
seizure present (10 patients)) separately did not yield
meaningful results, because of the small numbers.
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